Tervisetehnoloogiate Arenduskeskus AS on teadusuuringutele ja tootearendusele keskendunud biotehnoloogiafirma, mille peamisteks tegevusvaldkondadeks on personaalmeditsiin, ravimiarendus ja reproduktiivmeditsiin nii inim- kui ka veterinaarmeditsiini alal. Ettevõtte koostööpartneriteks on nii Eesti juhtivad teadlased kui ka biotehnoloogiafirmad, samuti teadus-, meditsiini- ja arendusasutused Euroopas, Aasias ja Ameerikas.


Unikaalne kulutõhus geneetika test, mis hindab emaka limaskesta kvaliteeti (pesastumise test)



Embrüo siirdamiseelse kromosoomianalüüsiga hinnatakse embrüote kromosoomide arvu



NIPTIFY on kõige uuem ja tundlikum loote DNA sõeluuring



Joint webinar Female fertility preservation 11.11.2020

Baltic Fertility Society and Nordic Fertility Society invite all interested…

Loe edasi ❯❯

Nordfertil meeting

7th Meeting of the “Nordic Centre for Fertility Preservation in…

Loe edasi ❯❯

PhD defence of Olga Tšuiko

On 26 November, 2018 Olga Tšuiko defended her doctoral thesis…

Loe edasi ❯❯

The Competence Centre on Health Technologies was granted a substantial investment by Enterprise Estonia from the frameprogramme for Competence Centres. The entire budget for the 7-year project is 12.1 million Euros and according to this decision, the grant from Enterprise Estonia covers up to 6.9 million Euros from the total budget.

For additional information, please contact Hardi Tamm, Development Manager  (hardi.tamm [at] ccrmb.ee)

rof. Salumets introduces CCHT’s latest research on endometrial biology and embryo implantation in his talk at this year’s European Society of Human Reproduction and Embryology (ESHRE) meeting. Among other things, the embryo-endometrium interactions that play a crucial role during embryo implatation will be discussed.

The entire ESHRE2015 meeting programme can be found here.

For more information, please contact our Development Manager Hardi Tamm (hardi.tamm [at] ccrmb.ee).

The Estonian Ministry of Education and Science gave a positive evaluation to the research and development activities conducted at the CCHT.

For additional information regarding the evaluation, please contact CCHT’s Development manager Hardi Tamm (hardi.tamm [at] ccrmb.ee).

The British parliament recently decided to allow a procedure that could result in the birth of babies with three biological parents. Andres Salumets, professor of reproductive medicine and head of the Competence Centre on Health Technologies, was asked to comment on the issue. Prof. Salumets briefly described the biology of mitochondrial diseases and the technical aspects associated with the procedure.

The news in Estonian can be found here and comments by prof. Salumets (also in Estonian) here.

President Barack Obama said in his State of the Union speech on Tuesday that his administration wants to launch a new push to use personalized genetic information to help treat diseases like cancer and diabetes.

Obama urged Congress in his address to boost research funding to support new investments in “precision medicine.” “I want the country that eliminated polio and mapped the human genome to lead a new era of medicine – one that delivers the right treatment at the right time,” Obama said, noting the approach had helped reverse cystic fibrosis in some patients.

The sequencing of individual genomes, read-outs of a person’s complete genetic information, could speed scientific research and help drug companies and physicians tailor medicines to an individual’s genetic profile. Using genomic data to identify which patients will benefit could save tens of billions of dollars now spent on ineffective drugs.

Obama’s call follows a move announced last year in England under which a company owned by the Department of Health aimed to sequence 100,000 whole genomes from National Health Service patients by 2017

Full text here

The Estonian transgenic cow project has gained interest worldwide. The Competence Centre on Health Technologies (CCHT) begins collaborations on the transgenic cow project with the National Institute of Animal Sciences in Hanoi, Vietnam, with an aim to transfer and further develop the transgenic technologies. The project also applies for funding from the FIRST (Fostering Innovation through Research, Science and Technology) project, which was launced by the World Bank to support science, technology and innovation in Vietnam.

As a result of this collaboration, transgenic animals should be born both in Estonia and in Vietnam, and production of human insulin using the Estonian technology should begin in 2020.

For additional information, please contact Hardi Tamm, Development manager at CCHT (hardi.tamm [at] ccrmb.ee).

The probiotic strains selected in the Competence Centre for Health Technologies for treating major urogenital tract disturbances, such as bacterial vaginosis and candidiasis, have succesfully completed the initial laboratory testing for safety and will soon enter clinical trials.

For additional information, please contact Hardi Tamm, Development manager at CCHT (hardi.tamm [at] ccrmb.ee).

Krista Kruuv-Käo, MD and former CEO of the Estonian Genome Foundation, joined the Competence Centre on Health Technologies (CCHT) as a Programme Manager for the Personalised Medicine Development Area. CCHT aims to develop a competence centre for personalised medicine.

For additional information, please contact Hardi Tamm, Development manager at CCHT (hardi.tamm [at] ccrmb.ee).

Full text on genomeweb.

With its information technology infastructure and biological resources, Estonia could be a model system for how the rest of the world should integrate genomic medicine into public health and prevention efforts, according to Eric Lander, president of the Broad Institute of MIT and Harvard.

On 12 December 2014, Professor Lander gave a public lecture at the Estonian Genome Center entitled “Genetic Basis of Human Disease: The past and future of genomic medicine”.

“In many ways, Estonia is at the cutting edge of what is possible,” Lander, said during a talk on Friday at the University of Tartu. Estonia has been a world leader in information and communication technology, [and] because of that they have the opportunity to do the types of medical studies that are very hard to do in the US.”

“The idea that a whole country got itself this organized is very impressive,” said Lander. For instance, he noted that Estonian clinicians, provided with new genomic information, have the ability to go back to a patient to advise them of, say, an enhanced risk of developing glaucoma, which could result in various preventative healthcare steps. And given the centralization and accessibility of such information, it is possible to share the information between doctors, no matter where they are located. “We in the US are all working hard, but we don’t have interoperable health records,” he added. Even within the Partners Healthcare system in Boston, two hospitals sometimes cannot exchange data because there are different systems,” he said. “All of the hard work to make things interoperable has been done here.”

The original text can be found here

As of October 23rd, the Competence Centre on Reproductive Medicine has a new name – Competence Centre on Health Technologies.
The Competence Centre on Health Technologies (CCHT) is a company focused on applied research and product development in clinical and translational medicine, as well as in biotechnology. The main development areas in CCHT are personal medicine, drug development and reproductive medicine.
 For additional information, please contact Hardi Tamm, Development manager at CCHT (hardi.tamm [at] ccrmb.ee).